About this event
The landscape of advanced/metastatic NSCLC has changed dramatically with the approval of immunotherapies and targeted agents in recent years. After metastatic disease, early-stage NSCLC has become a new testing ground for these therapies. Most key players are in the race to position their drugs in this hitherto unexplored territory where surgery, radiotherapy (RT), or chemoradiation (ChemoRT) has remained the mainstay of treatment.
Let's together explore how early-stage NSCLC is shaping up with the entrenchment of new therapies and what new questions have emerged with this paradigm shift. FutureBridge’s Oncology Analysts in this webinar will cover the:
A molecular biologist with expertise in oncology business research and consulting, R&D strategy, and competitive and treatment landscapes for companies developing oncology assets.
I am life sciences professional with ~20 years overall experience in drug discovery, pharma, oncology/immuno-oncology consulting. I provide consultation to global clients to support their strategic business decisions.
FutureBridge is a techno-commercial consulting and advisory company.
We track and advise on the future of industries from a 1-to-25-year perspective to keep you ahead of the technology curve, propel your growth, Identify new opportunities, markets and business models, answer your unknowns, and fac
Share this event